March 23, 2025 - 10:21

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) have taken a significant step by sending a letter to the U.S. Food and Drug Administration (FDA). This letter, supported by over 20 prominent organizations and providers from various sectors of healthcare, emphasizes the urgent need for the FDA to implement and enforce federal regulations concerning compounding practices.
The call to action comes in the wake of recent shortages of GLP-1 medications, which are crucial for the treatment of obesity and related conditions. These shortages have raised serious concerns about patient access to essential therapies. The coalition argues that without stricter oversight and regulation of compounded medications, patients may face continued disruptions in their treatment options.
Healthcare leaders are advocating for a timely response from the FDA to ensure that patients receive the medications they need without interruption, highlighting the importance of regulatory frameworks in safeguarding public health.
November 18, 2026 - 01:35
Vermont Schools See Minimal Health Insurance Increase Amid Rising CostsStatewide efforts to reduce healthcare costs have resulted in the lowest increase in health insurance for public schools in years. However, while this development offers some relief, it is not...
November 17, 2026 - 11:28
Local Leaders Unite to Address Workplace Mental Health Amid Burnout CrisisDr. Brian Watkins of Rochester Regional Health is set to discuss an innovative peer support group designed specifically for surgeons. This initiative, which has now expanded to operate across the...
November 16, 2026 - 22:01
New Health Declaration Required for International Travelers to the U.S.A recent rule from the Centers for Disease Control and Prevention mandates that all international travelers, including U.S. citizens returning home, must complete a health declaration form before...
November 16, 2026 - 08:38
Enhancing DHA Delivery for Brain Health in the APAC RegionRecent advancements in microlipid technology are paving the way for improved delivery of docosahexaenoic acid (DHA), a vital nutrient for brain health. This innovative approach combines clinical...